SG149074A1 - Human epo mimetic hinge core mimetibodies, compositions, methods and uses - Google Patents
Human epo mimetic hinge core mimetibodies, compositions, methods and usesInfo
- Publication number
- SG149074A1 SG149074A1 SG200809659-6A SG2008096596A SG149074A1 SG 149074 A1 SG149074 A1 SG 149074A1 SG 2008096596 A SG2008096596 A SG 2008096596A SG 149074 A1 SG149074 A1 SG 149074A1
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- human epo
- hinge core
- epo mimetic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50734903P | 2003-09-30 | 2003-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG149074A1 true SG149074A1 (en) | 2009-01-29 |
Family
ID=34421611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200809659-6A SG149074A1 (en) | 2003-09-30 | 2004-09-03 | Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
Country Status (29)
Country | Link |
---|---|
EP (2) | EP1675579B1 (es) |
JP (1) | JP4810428B2 (es) |
KR (1) | KR101201339B1 (es) |
CN (1) | CN1894275B (es) |
AR (1) | AR046415A1 (es) |
AT (1) | ATE439370T1 (es) |
AU (1) | AU2004277884B2 (es) |
BR (1) | BRPI0414893A (es) |
CA (1) | CA2540665A1 (es) |
CO (1) | CO5690612A2 (es) |
CR (1) | CR8320A (es) |
CY (1) | CY1109579T1 (es) |
DE (1) | DE602004022571D1 (es) |
DK (1) | DK1675579T3 (es) |
EA (1) | EA009377B1 (es) |
EC (1) | ECSP066466A (es) |
ES (1) | ES2329799T3 (es) |
HK (1) | HK1091413A1 (es) |
IL (2) | IL174676A (es) |
NO (1) | NO20061931L (es) |
NZ (1) | NZ546287A (es) |
PL (1) | PL1675579T3 (es) |
PT (1) | PT1675579E (es) |
SG (1) | SG149074A1 (es) |
SI (1) | SI1675579T1 (es) |
TW (1) | TWI344987B (es) |
UA (1) | UA89481C2 (es) |
WO (1) | WO2005032460A2 (es) |
ZA (1) | ZA200603425B (es) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008537874A (ja) | 2004-09-27 | 2008-10-02 | セントカー・インコーポレーテツド | sRAGEミメティボディ、組成物、方法および使用 |
US7910101B2 (en) * | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
US20100034819A1 (en) * | 2006-03-31 | 2010-02-11 | Centocor Inc. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia |
US8834920B2 (en) | 2006-12-21 | 2014-09-16 | Alza Corporation | Liposome composition for targeting egfr receptor |
US8536113B2 (en) | 2006-12-21 | 2013-09-17 | Janssen Biotech, Inc. | EGFR binding peptides and uses thereof |
WO2008079976A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Dimeric high affinity egfr constructs and uses thereof |
KR100888022B1 (ko) * | 2006-12-21 | 2009-03-09 | 재단법인 목암생명공학연구소 | 면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc |
AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
US9175078B2 (en) | 2008-01-25 | 2015-11-03 | Amgen Inc. | Ferroportin antibodies and methods of use |
JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
EP2349332B1 (en) | 2008-11-13 | 2019-10-23 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
EP2401302A4 (en) * | 2009-02-24 | 2013-10-09 | Alexion Pharma Inc | ANTIBODIES CONTAINING TPO / EPO MIMETIC THERAPEUTIC PEPTIDES |
CN102497877B (zh) * | 2009-09-15 | 2015-03-18 | 株式会社钟化 | 附加了水溶性长链分子的修饰的促红细胞生成素 |
MX344382B (es) | 2009-10-23 | 2016-12-14 | Amgen Inc * | Adaptador de vial y sistema. |
JP5850846B2 (ja) | 2009-11-17 | 2016-02-03 | ヤンセン バイオテツク,インコーポレーテツド | 繊維状ファージ上でのジスルフィド結合二量体タンパク質の提示 |
WO2011062862A1 (en) | 2009-11-17 | 2011-05-26 | Centocor Ortho Biotech Inc. | Improved bacterial membrane protein secrection |
US8895700B2 (en) | 2010-02-18 | 2014-11-25 | Janssen Biotech, Inc. | Monkey homolog of human interferon omega |
WO2011130533A1 (en) | 2010-04-16 | 2011-10-20 | Centocor Ortho Biotech Inc. | Engineered plant cysteine proteases and their uses |
WO2011156373A1 (en) | 2010-06-07 | 2011-12-15 | Amgen Inc. | Drug delivery device |
FR2964585B1 (fr) * | 2010-09-15 | 2012-10-05 | Snecma | Procede et machine outil pour l'ajustage du contour d'une piece |
US9480624B2 (en) | 2011-03-31 | 2016-11-01 | Amgen Inc. | Vial adapter and system |
EP2699293B8 (en) | 2011-04-20 | 2022-07-20 | Amgen Inc. | Autoinjector apparatus |
KR101931403B1 (ko) * | 2011-09-23 | 2018-12-21 | 블루버드 바이오, 인코포레이티드. | 개선된 유전자 치료 방법 |
HUE043691T2 (hu) | 2011-10-14 | 2019-09-30 | Amgen Inc | Befecskendezõ eszköz és összeszerelési eljárás |
US8986704B2 (en) * | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
WO2014030780A1 (en) * | 2012-08-22 | 2014-02-27 | Mogam Biotechnology Research Institute | Screening and engineering method of super-stable immunoglobulin variable domains and their uses |
EP4234694A3 (en) | 2012-11-21 | 2023-09-06 | Amgen Inc. | Drug delivery device |
TWI639453B (zh) | 2013-03-15 | 2018-11-01 | 美商安美基公司 | 用於注射器之匣盒 |
JP6336564B2 (ja) | 2013-03-15 | 2018-06-06 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入器、および自動注入器システム |
EP2968503B1 (en) | 2013-03-15 | 2018-08-15 | Intrinsic LifeSciences LLC | Anti-hepcidin antibodies and uses thereof |
TWI592183B (zh) | 2013-03-15 | 2017-07-21 | 安美基公司 | 本體輪廓可調適之自動注射器裝置 |
SG11201507359SA (en) * | 2013-03-15 | 2015-10-29 | Dana Farber Cancer Inst Inc | Flavivirus neutralizing antibodies and methods of use thereof |
EP2976117B1 (en) | 2013-03-22 | 2020-12-30 | Amgen Inc. | Injector and method of assembly |
EP3501575B1 (en) | 2013-10-24 | 2021-12-01 | Amgen Inc. | Drug delivery system with temperature-sensitive-control |
AU2014340171B2 (en) | 2013-10-24 | 2019-05-30 | Amgen Inc. | Injector and method of assembly |
EP3092246B1 (en) | 2014-01-09 | 2019-06-05 | Valneva Austria GmbH | Mutant fragments of ospa and methods and uses relating thereto |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
MX2016014561A (es) | 2014-05-07 | 2017-06-21 | Amgen Inc | Autoinyetor con elementos reductores del shock. |
MX2016015854A (es) | 2014-06-03 | 2017-07-19 | Amgen Inc | Sistema de suministro de farmacos controlable y metodo de uso. |
CA2961917A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
EP3943135A3 (en) | 2014-10-14 | 2022-06-29 | Amgen Inc. | Drug injection device with visual and audible indicators |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
EP3233163B1 (en) | 2014-12-19 | 2021-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
WO2016133947A1 (en) | 2015-02-17 | 2016-08-25 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
JP2018512184A (ja) | 2015-02-27 | 2018-05-17 | アムジエン・インコーポレーテツド | 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置 |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
EP3386573B1 (en) | 2015-12-09 | 2019-10-02 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017160799A1 (en) | 2016-03-15 | 2017-09-21 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
MX2018013616A (es) | 2016-05-13 | 2019-02-21 | Amgen Inc | Montaje de cubierta protectora de vial. |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
EP3582825A1 (en) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
AU2018230546B2 (en) | 2017-03-07 | 2024-03-21 | Amgen Inc. | Needle insertion by overpressure |
US11986624B2 (en) | 2017-03-09 | 2024-05-21 | Amgen Inc. | Insertion mechanism for drug delivery device |
WO2018172219A1 (en) | 2017-03-20 | 2018-09-27 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
DK3600491T3 (da) | 2017-03-28 | 2023-10-23 | Amgen Inc | Stempelstang og sprøjtekonstruktionssystem samt fremgangsmåde |
CA3059817A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
MX2019014615A (es) | 2017-06-08 | 2020-02-07 | Amgen Inc | Dispositivo de administracion de farmacos accionado por par de torsion. |
EP3634539A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
WO2018236619A1 (en) | 2017-06-22 | 2018-12-27 | Amgen Inc. | REDUCING THE IMPACTS / IMPACTS OF ACTIVATION OF A DEVICE |
US11395880B2 (en) | 2017-06-23 | 2022-07-26 | Amgen Inc. | Electronic drug delivery device |
EP3651832B1 (en) | 2017-07-14 | 2023-12-13 | Amgen Inc. | Needle insertion-retraction system having dual torsion spring system |
US11672733B2 (en) | 2017-07-21 | 2023-06-13 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
EP3658206A1 (en) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
ES2971450T3 (es) | 2017-10-06 | 2024-06-05 | Amgen Inc | Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente |
MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
US11305026B2 (en) | 2017-11-03 | 2022-04-19 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
EP3706830B1 (en) | 2017-11-06 | 2024-08-07 | Amgen Inc. | Drug delivery device with placement and flow sensing |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
CA3079665A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
MA50903A (fr) | 2017-11-16 | 2021-05-12 | Amgen Inc | Auto-injecteur avec détection de décrochage et de point d'extrémité |
JP7370969B2 (ja) | 2017-11-16 | 2023-10-30 | アムジエン・インコーポレーテツド | 薬物送達デバイスの扉ラッチ機構 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US12042645B2 (en) | 2018-07-24 | 2024-07-23 | Amgen Inc. | Delivery devices for administering drugs |
MA53375A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
US12115360B2 (en) | 2018-07-24 | 2024-10-15 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
JP2022500095A (ja) | 2018-09-24 | 2022-01-04 | アムジエン・インコーポレーテツド | インターベンション投薬システム及び方法 |
IL281469B2 (en) | 2018-09-28 | 2024-08-01 | Amgen Inc | Assembling a memory alloy ejector activation assembly for a drug delivery device |
WO2020072577A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
MA53818A (fr) | 2018-10-05 | 2022-01-12 | Amgen Inc | Dispositif d'administration de médicament ayant un indicateur de dose |
EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
AR116704A1 (es) | 2018-10-15 | 2021-06-02 | Amgen Inc | Dispositivo de administración de fármacos con mecanismo de amortiguación |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
AU2019370159A1 (en) | 2018-11-01 | 2021-04-22 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
MX2021012557A (es) | 2019-04-24 | 2021-11-12 | Amgen Inc | Conjuntos y metodos de verificacion de esterilizacion de jeringuillas. |
WO2021041067A2 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
US20240208680A1 (en) | 2021-05-21 | 2024-06-27 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
WO2024094457A1 (en) | 2022-11-02 | 2024-05-10 | F. Hoffmann-La Roche Ag | Method for producing glycoprotein compositions |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
US5075236A (en) | 1987-04-24 | 1991-12-24 | Teijin Limited | Method of detecting kawasaki disease using anti-tumor necrosis antibody |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE69027121T3 (de) | 1989-08-07 | 2001-08-30 | Peptech Ltd., Dee Why | Bindeligande für tumornekrosisfaktor |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
SG47099A1 (en) | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
JP3230056B2 (ja) | 1991-07-02 | 2001-11-19 | インヘイル・インコーポレーテッド | 薬剤のエーロゾル化服用量を形成する装置 |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
WO1994006498A1 (en) | 1992-09-23 | 1994-03-31 | Fisons Plc | Inhalation device |
HU217917B (hu) | 1992-10-19 | 2000-05-28 | Dura Pharmaceuticals Inc. | Inhalálókészülék száraz porok inhalálásához |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
EP0680451B1 (en) | 1993-01-19 | 1998-11-04 | Glaxo Group Limited | Aerosol dispenser and method of manufacture |
WO1994018317A1 (en) | 1993-02-12 | 1994-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5786331A (en) | 1994-02-02 | 1998-07-28 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5880096A (en) | 1994-02-02 | 1999-03-09 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
AU6163196A (en) * | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
JP2000503565A (ja) | 1996-01-03 | 2000-03-28 | グラクソ、グループ、リミテッド | 吸入装置 |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1278778A2 (en) * | 2000-05-03 | 2003-01-29 | Amgen Inc., | Modified peptides, comprising an fc domain, as therapeutic agents |
US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
DK1642910T3 (da) * | 2000-12-05 | 2012-05-07 | Alexion Pharma Inc | Rationelt designede atistoffer |
US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
EP1572079A4 (en) * | 2002-03-29 | 2006-09-06 | Centocor Inc | MAMMAL-CDR MIMETIC BODIES, COMPOSITIONS, PROCESSES AND APPLICATION PURPOSES |
CA2490411A1 (en) * | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
JP2006504406A (ja) * | 2002-06-28 | 2006-02-09 | セントカー・インコーポレーテツド | 哺乳動物のch1欠失ミメティボディ、組成物、方法および使用 |
-
2004
- 2004-03-09 UA UAA200604029A patent/UA89481C2/uk unknown
- 2004-09-03 DK DK04783275T patent/DK1675579T3/da active
- 2004-09-03 CA CA002540665A patent/CA2540665A1/en not_active Abandoned
- 2004-09-03 AT AT04783275T patent/ATE439370T1/de active
- 2004-09-03 KR KR1020067008486A patent/KR101201339B1/ko not_active IP Right Cessation
- 2004-09-03 SG SG200809659-6A patent/SG149074A1/en unknown
- 2004-09-03 EA EA200600525A patent/EA009377B1/ru not_active IP Right Cessation
- 2004-09-03 ES ES04783275T patent/ES2329799T3/es not_active Expired - Lifetime
- 2004-09-03 EP EP04783275A patent/EP1675579B1/en not_active Expired - Lifetime
- 2004-09-03 JP JP2006533891A patent/JP4810428B2/ja not_active Expired - Fee Related
- 2004-09-03 SI SI200431268T patent/SI1675579T1/sl unknown
- 2004-09-03 BR BRPI0414893-2A patent/BRPI0414893A/pt not_active IP Right Cessation
- 2004-09-03 DE DE602004022571T patent/DE602004022571D1/de not_active Expired - Lifetime
- 2004-09-03 AU AU2004277884A patent/AU2004277884B2/en not_active Ceased
- 2004-09-03 WO PCT/US2004/028976 patent/WO2005032460A2/en active Application Filing
- 2004-09-03 NZ NZ546287A patent/NZ546287A/en not_active IP Right Cessation
- 2004-09-03 PT PT04783275T patent/PT1675579E/pt unknown
- 2004-09-03 EP EP09075328A patent/EP2123675A3/en not_active Withdrawn
- 2004-09-03 CN CN200480035434XA patent/CN1894275B/zh not_active Expired - Fee Related
- 2004-09-03 PL PL04783275T patent/PL1675579T3/pl unknown
- 2004-09-29 TW TW093129457A patent/TWI344987B/zh not_active IP Right Cessation
- 2004-09-30 AR ARP040103559A patent/AR046415A1/es not_active Application Discontinuation
-
2006
- 2006-03-30 EC EC2006006466A patent/ECSP066466A/es unknown
- 2006-03-30 IL IL174676A patent/IL174676A/en not_active IP Right Cessation
- 2006-03-30 CR CR8320A patent/CR8320A/es not_active Application Discontinuation
- 2006-04-24 CO CO06038331A patent/CO5690612A2/es not_active Application Discontinuation
- 2006-04-28 ZA ZA2006/03425A patent/ZA200603425B/en unknown
- 2006-04-28 NO NO20061931A patent/NO20061931L/no not_active Application Discontinuation
- 2006-11-03 HK HK06112140.8A patent/HK1091413A1/xx not_active IP Right Cessation
-
2009
- 2009-07-28 IL IL200117A patent/IL200117A/en not_active IP Right Cessation
- 2009-11-06 CY CY20091101155T patent/CY1109579T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1091413A1 (en) | Human epo mimetic hinge core mimetibodies, compositions, methods and uses | |
EP1687452A4 (en) | HUMAN HINGE-CORE MIMETICORPS, COMPOSITIONS, METHODS AND APPLICATIONS THEREOF | |
IL175491A0 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides | |
GB0411940D0 (en) | Methods and compositions | |
EP1619947A4 (en) | ANTIBACTERIAL COMPOSITIONS AND ASSOCIATED METHODS | |
EP1701725A4 (en) | PROCESS AND COMPOSITIONS | |
EP1617807A4 (en) | SUBSTITUTED 1,4-DIAZEPINE AND ITS USES | |
GB0317729D0 (en) | Sliding composition and sliding member | |
HK1091487A1 (en) | Substituted thiophenes and uses thereof | |
GB0310791D0 (en) | Improved cosmetic composition | |
AU2003249114A8 (en) | Cosmetic composition | |
EP1683510A4 (en) | COSMETIC COMPOSITION | |
EP1594849A4 (en) | COMPOUNDS, COMPOSITIONS, AND METHODS | |
AU2003293765A8 (en) | Novel skin lightening agents, compositions and methods | |
EP1620092A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS | |
EP1685823A4 (en) | COSMETIC COMPOSITION | |
GB2398740B (en) | Skin composition | |
GB0308062D0 (en) | Cosmetic composition | |
EP1622878A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS | |
AU2002332244A8 (en) | Demelanizing agents, beautifying agents, demelanizing compositions and beautifying compositions | |
GB2403727B (en) | Personal care composition | |
GB2407579B (en) | Sliding composition and sliding member | |
GB0325238D0 (en) | Composition and use | |
GB0311167D0 (en) | Composition and use | |
GB0311163D0 (en) | Composition and use |